<div id="readability-page-1"><article>TGA approval enables regional launch of Owlet’s clinically validated, award-winning infant health monitor; Owlet360™ subscription marks first international expansion of the Company’s recurring-revenue platform. SYDNEY--(BUSINESS WIRE)--Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), the pioneer of smart infant monitoring, today announces that Dream Sock™ is now available for families across Australia and New Zealand. Dream Sock recently received approval from Australia’s Therapeutic Goods Administration (TGA), meeting rigorous medical device standards in the region. With this milestone achieved, families can now purchase Dream Sock through Owlet’s local website and select retail partners.<div id="bwbodyimg"><img src="https://imageproxy.pbkrs.com/https://mms.businesswire.com/media/20251204190645/en/2661261/4/Owlet_Dream_Sock.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://mms.businesswire.com/media/20251204190645/en/2661261/4/Owlet_Dream_Sock.jpg"/>Owlet launches TGA-Approved Dream Sock in ANZ.</div>“Bringing Owlet’s TGA-approved pediatric health monitor to Australia and New Zealand represents a meaningful step in our international growth strategy, as parents are actively seeking trusted, medically-validated solutions,” said Jonathan Harris, Owlet’s President and CEO. “We are bringing the clinical-grade monitoring of Dream Sock to ANZ families through both direct-to-consumer and leading specialty retail channels, while also extending Owlet360 subscription services further to support our growing base of customers in the region.”Dream Sock is a wearable smart baby monitor designed for infants ages 0-18 months (2.5–13.6 kg). Using advanced, clinically validated technology, Dream Sock tracks key vitals, including pulse rate, oxygen level, and sleep trends. Insights are viewable in real-time through the Owlet Dream App (available via iOS and Android), while both the App and the included Base Station provide notifications if readings fall outside preset ranges. Dream Sock combines the reassurance parents want with the medical-grade accuracy they expect, empowering families with the information to make more informed care decisions.In conjunction with the Dream Sock launch, Owlet is introducing Owlet360 in Australia and New Zealand, marking the first international rollout of the Company’s subscription service. The Owlet Dream App will continue to provide core pulse rate and oxygen tracking and critical notifications at no cost. Owlet360 adds a higher-value experience through personalized guidance, expert-backed resources, and deeper analytics designed to complement Dream Sock’s real-time vitals monitoring. Subscription features include daily sleep reports and expanded trend insights across pulse rate, oxygen, movement, comfort temperature, and room environment metrics. The Owlet360 expansion supports Owlet’s strategy to diversify revenue and increase recurring, higher-margin subscription contribution over time.Dream Sock and Owlet360 are now available in Australia and New Zealand via Owlet’s ecommerce websites and through select retail partners. Dream Sock can also be paired with the Company’s Cam® 2 and purchased as the Dream Duo™. Families can visit www.owletcare.com or www.owletcare.com.au to purchase, explore features, or learn more about how Dream Sock and Owlet360 work together to support infant well-being.About Owlet, Inc.Owlet, Inc. (NYSE: OWLT), a leading pediatric health platform, is the only company in the world to offer U.S. FDA-cleared and internationally medically-certified wearable pediatric monitors, delivering hospital-grade technology directly in the home. Our award-winning pediatric products and innovative software combine clinically tested monitoring systems, an integrated video platform, and a simple, easy-to-use app, providing parents with real-time health insights to stay informed on their child’s well-being, support restful sleep, and provide peace of mind anywhere. Since 2012, more than 2.5 million parents have trusted Owlet to monitor their children's well-being and sleep. This adoption has fueled one of the largest collections of pediatric health and sleep data in the world, powering innovations that bridge the critical gap between hospital and home. Owlet is driving a new standard in pediatric wellness by pairing advanced medical technology with consumer-friendly design. Our mission is simple yet ambitious: to give every baby and every family the best possible start in life. Learn more at www.owletcare.com and follow us on LinkedIn and Instagram for company news and updates.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the Company’s expectations regarding the certification and launch of Dream Sock™ and the introduction of Owlet360™in Australia, New Zealand and other international markets; the availability, adoption and commercial success of Dream Sock and Owlet360; the Company’s ability to expand its international footprint, broaden its product and subscription offerings, diversity revenue streams and increase recurring, higher-margin subscription contribution over time; and the Company’s growth prospects; and potential market reception and competitive positioning. In some cases, you can identify forward-looking statements by terms such as “estimate,” “may,” “believes,” “plans,” “expects,” “anticipates,” “intends,” “goal,” “potential,” “upcoming,” “outlook,” “guidance,” the negation thereof, or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on the Company’s expectations at the time such statements are made, speak only as of the dates they are made, and are susceptible to a number of risks, uncertainties, and other factors. For all such forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. The Company’s actual results, performance or achievements may differ materially from any future results, performance or achievements expressed or implied by its forward-looking statements. Many important factors could affect the Company’s future results and cause those results to differ materially from those expressed in or implied by the Company’s forward-looking statements. Such factors include, but are not limited to, (i) the availability, adoption, and commercial success of Dream Sock and Owlet360 in Australia, New Zealand, and other international markets, and the commercial success of Owlet’s other products, platform and related software services; (ii) the regulatory pathway for Owlet’s products, including submissions to, actions taken by and decisions and responses from regulators, such as the FDA and similar regulators outside of the United States, as well as Owlet’s ability to obtain and maintain regulatory approval or certification for its products and other regulatory requirements and legal proceedings; (iii) the Company’s and its partners’ obligations relating to data privacy, security and the exchange and use of health information (including HIPAA, HITECH and comparable laws, and evolving requirements governing such activities), and risks of cybersecurity incidents or changes in applicable standards or interpretations; (iv) the performance of, and Owlet’s ability to maintain and expand, its relationship with third-party technology, cloud, manufacturing and distribution partners; (v) Owlet’s competition and the Company’s ability to profitably grow and manage growth; (vi) the ability of Owlet to implement strategic initiatives, reduce costs, grow revenues, develop and launch new products, innovate and enhance existing products, meet customer demands and adapt to changes in consumer preferences and retail trends; (vii) Owlet’s ability to acquire, defend and protect its intellectual property and satisfy regulatory requirements concerning privacy and data protection; (viii) Owlet’s ability to maintain relationships with channel partners, customers, manufacturers and suppliers; (ix) impacts from compliance with applicable laws or regulations; (x) the impact of and disruption to Owlet’s business, financial condition, operations, supply chain and logistics due to economic and other conditions beyond the Company’s control; (xi) adverse impacts from other economic, business, regulatory, competitive or other factors, such as changes in discretionary consumer spending and consumer preferences; and (xii) other risks and uncertainties set forth in the Company’s other releases, public statements and filings with the U.S. Securities and Exchange Commission (“SEC”), including those identified in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and as any such factors may be updated from time to time in the Company’s other filings with the SEC. All such forward-looking statements attributable to the Company or any person acting on the Company’s behalf are expressly qualified in their entirety by the cautionary statements contained or referred to above. Moreover, the Company operates in an evolving environment. New risk factors and uncertainties may emerge from time to time, and factors that the Company currently deems immaterial may become material, and it is impossible for the Company to predict such events or how they may affect Owlet. Except as required by law, the Company assumes no obligation to update any forward-looking statements after the date of this press release, whether because of new information, future events or otherwise, although Owlet may do so from time to time. The Company does not endorse any projections regarding future performance that may be made by third parties.<img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMDQxOTA2NDVyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMDQxOTA2NDVyMQ"/>View source version on businesswire.com: https://www.businesswire.com/news/home/20251204190645/en/Media Contact: pr@owletcare.comInvestor Contact: ir@owletcare.comSource: Owlet, Inc.</article></div>

OWLT

Owlet, Inc. has launched its TGA-approved Dream Sock™ in Australia and New Zealand, marking a significant step in its international expansion. The Dream Sock, a smart infant health monitor, is now available through Owlet's local website and select retail partners. This launch also introduces the Owlet360 subscription service in the region, enhancing the company's recurring-revenue platform. The Dream Sock provides real-time health insights for infants, and the Owlet360 offers personalized guidance and analytics, supporting Owlet's strategy to diversify revenue and increase subscription contributions.

StockTitan

Owlet

Owlet Launches TGA-Approved Dream Sock™ in Australia & New Zealand, Expanding International Footprint and Bringing Trusted Pediatric Health Monitoring to More Families Worldwide | OWLT Stock News